{"entity":{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","aka":["Henan Genuine Biotech Co., Ltd."],"tldr":"Henan Genuine Biotech is a Chinese developer in Henan that sponsors 2 registered cancer trials of GEN-725 and Dositinib.","summary":"Henan Genuine Biotech appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2), testing GEN-725, Dositinib in non-small cell lung cancer. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials sponsored by Henan Genuine Biotech","url":"https://clinicaltrials.gov/search?spons=Henan%20Genuine%20Biotech"}],"tags":["ctgov-sponsor","china","registry-only"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07362940","nct07231068"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Henan, China","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/henan-genuine-biotech/","neighbours":{"trial":[{"id":"nct07231068","kind":"trial","name":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","route":"/trials/nct07231068/"},{"id":"nct07362940","kind":"trial","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","route":"/trials/nct07362940/"}]}}